NEWS

Quarterly update QUARTERLY UPDATE (Q3 2024)

Press Release NeoImmuneTech Presents Promising Interim Results of CAR-T Combination with its NT-I7 Asset at ESMO 2024

Quarterly update QUARTERLY UPDATE (Q2 2024)

News Update NeoImmuneTech Files International Patent Application for 'Multispecific Antibody Platform Technology'

Press Release NeoImmuneTech’s New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors in Immuno-Oncology

Press Release EMA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome

News Update NeoImmuneTech’s Polish Subsidiary Obtains SME status

News Update Duke University Receives $6 Million contract from National Institutes of Health to Study NeoImmuneTech's NT-I7 in Treating Acute Radiation Syndrome

Press Release NeoImmuneTech’s NT-I7 in Combination with Chemotherapy Shows Efficacy in Colorectal Cancer at AACR Meeting

Quarterly update QUARTERLY UPDATE (Q1 2024)